CCR5 inhibitors: Emergence, success, and challenges

Expert Opinion on Emerging Drugs

Volumn 17, Issue 2, 2012, Pages 135-145

  Maeda, Kenji ^a   Das, Debananda ^a   Nakata, Hirotomo ^a,b   Mitsuya, Hiroaki ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

AIDS; Antiretroviral therapy; CCR5; CCR5 inhibitor; Chemokine; HIV

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; APLAVIROC; ATAZANAVIR; CD4 ANTIGEN; CENICRIVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INCB 009471; INTEGRASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLACEBO; RANTES; RITONAVIR; UNCLASSIFIED DRUG; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CELL ASSAY; CELL LINE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MORTALITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; TROPISM; VIRUS LOAD; WILD TYPE;

ANIMALS; ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOHEXANES; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRIAZOLES;

EID: 84861647068     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.673584     Document Type: Review

References (96)

1. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-100 (Pubitemid 16209699)
2. Mitsuya H, Erickson J. Discovery and development of antiretroviral therapeutics for HIV infection. In: Merigan TC, Bartlet JG, Bolognesi D, editors. Textbook of AIDS Medicine. Williams & Wilkins; Baltimore: 1999. p. 751-80
3. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26 (Pubitemid 32619279)
4. Hogg R, Lima V, Sterne JA, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9
5. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-9 (Pubitemid 351920404)
6. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006;194:11-19
7. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008;47:712-28
8. Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003;9:839-43 (Pubitemid 36889923)
9. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:1159-66 (Pubitemid 38951265)
10. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-33 (Pubitemid 26299570)
11. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 1996;384:184-7 (Pubitemid 26386476)
12. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6 (Pubitemid 26197679)
13. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384:179-83 (Pubitemid 26386475)
14. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58 (Pubitemid 26235280)
15. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-48 (Pubitemid 26231178)
16. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73 (Pubitemid 26197680)
17. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8 (Pubitemid 26234510)
18. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7 (Pubitemid 26154590)
19. Rizzuto CD, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-53 (Pubitemid 28299405)
20. Poignard P, Saphire EO, Parren PW, Burton DR. Gp120: biologic aspects of structural features. Annu Rev Immunol 2001;19:253-74 (Pubitemid 32368036)
21. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59 (Pubitemid 28289647)
22. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003;348:2228-38 (Pubitemid 36618135)
23. Jahn R, Lang T, Sudhof TC. Membrane fusion. Cell 2003;112:519-33 (Pubitemid 36263084)
24. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73 (Pubitemid 27199898)
25. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4 (Pubitemid 28257575)
26. Littman DR. Chemokine receptors: keys to AIDS pathogenesis? Cell 1998;93:677-80 (Pubitemid 28257574)
27. Hoffman TL, Doms RW. Chemokines and coreceptors in HIV/SIV-host interactions. AIDS 1998;12(Suppl A):S17-26
28. Doranz BJ, Berson JF, Rucker J, Doms RW. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res 1997;16:15-28 (Pubitemid 27129627)
29. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997;11:S3-16
30. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700 (Pubitemid 29241137)
31. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-8 (Pubitemid 27098147)
32. de Roda Husman AM, Schuitemaker H. Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol 1998;6:244-9 (Pubitemid 28288154)
33. O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000;177:99-111
34. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5
35. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62
36. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77 (Pubitemid 26272077)
37. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40 (Pubitemid 43139642)
38. Bracci PM, Skibola CF, Conde L, et al. Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma 2010;51:497-506
39. AIDS epidemic update. World Health Organization. Available from: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/ jc1700-epi-update-2009-en.pdf [Last accessed 12 December 2011]
40. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. UNAIDS. Available from: http://www.unaids.org/globalreport/Global-report.htm [Last accessed 12 December 2011]
41. Impact of the Global Financial and Economic Crisis on the AIDS Response. 25th Meeting of the UNAIDS Programme Coordinating Board: UNAIDS, 2009. Available from: http://www.unaids.org/en/[Last accessed 12 December 2011]
42. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC) (January 10, 2011)
43. Chapman D, Valdez H, Lewis M, et al. Clinical, virologic, and immunologic characteristics of patients with discordant phenotypic and genotypic co-receptor tropism test results. Paper presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-15 September 2010; Boston, MA
44. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010;24:2517-25
45. Vandekerckhove LP, Wensing AM, Kaiser R, et al. European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011;11:394-407
46. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-15
47. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32 (Pubitemid 41552605)
48. Strizki JM, Xu S, Wagner NE, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-23 (Pubitemid 33020012)
49. Tagat JR, McCombie SW, Nazareno D, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl) phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004;47:2405-8 (Pubitemid 38580075)
50. Maeda K, Nakata H, Koh Y, et al. A spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 HIV-1 in vitro. J Virol 2004;78:8654-62 (Pubitemid 39025131)
51. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-03 (Pubitemid 29234681)
52. Seto M, Aikawa K, Miyamoto N, et al. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem 2006;49:2037-48
53. Parra J, Portilla J, Pulido F, et al. Clinical utility of maraviroc. Clin Drug Investig 2011;31:527-42
54. Daniel R, Kuritzkes MD. HIV-1 Entry Inhibitors: an Overview. Curr Opin HIV AIDS 2009;4:82-7
55. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2 (Pubitemid 43093663)
56. Gulick RM, Lalezari J, Goodrich J, et al. MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
57. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-55
58. What is Trofile™. Trofile-Monogram Biosciences. Available from: http://www. trofileassay.com/what-is-trofile.html [Last accessed 12 December 2011]
59. Perno CF, Craig C, Taylor S, et al. Efficacy and Viral Resistance Are Comparable when Maraviroc Is Administered Once Daily or Twice Daily with Boosted Protease Inhibitors in Treatment-experienced Patients [abstract PE7.3/4]. 13th European AIDS Conference; 12-15 October 2011; Belgrade, Serbia
60. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [abstract #792]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA
61. Hoepelman IM, Ayoub A, Heera J. The incidence of severe liver enzyme abnormalities and hepatic adverse events in the Maraviroc Clinical Development Programme [abstract LBP7.9/1]. 11th European AIDS Conference/EACS; 24-27 October 2007; Madrid, Spain
62. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study [abstract #WESS104]. 4th IAS conference; 22-25 July 2007; Sydney, Australia
63. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-13
64. Heera J, Saag M, Ive P, et al. Virological correlates associated with treatment failure at week 48 in the phase III study of maraviroc in treatment naive patients [abstract #40LB]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA
65. Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010;55:558-64
66. Sierra-Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials 2010;11:125-32
67. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12 (Pubitemid 47047471)
68. McCarthy MC, Suleiman J, Diaz R, et al. Vicriviroc Long-Term Safety and Efficacy: 96-Week Results from the VICTOR-E1 Study [abstract H-923]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009); 12-15 September 2009; San Francisco, CA
69. Gathe J, Diaz R, Fatkenheuer G, et al. Phase III Trials of Vicriviroc in Treatment-experienced Subjects Demonstrate Safety but Not Significantly Superior Efficacy over Potent Background Regimens Alone [abstract 54LB]. 17th Conference on Retroviruses & Opportunistic Infections; 16-19 February 2010; San Francisco, CA
70. Nakata H, Maeda K, Miyakawa T, et al. Potent anti-R5-HIV-1 effects of a CCR5 antagonist AK602 in a novel hu-PBMC-Non-Obese-Diabetic-SCID, IL-2Rg-Chain-Knocked-Out AIDS mouse model. J Virol 2005;79:2087-96
71. Lalezari J, Thompson M, Kumar P, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005;19:1443-8 (Pubitemid 41400688)
72. Nichols WG, Steel HM, Bonny T, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 2008;52:858-65 (Pubitemid 351358363)
73. Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team. Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother 2009;53:1116-23
74. Cohen C, DeJesus E, Mills A, et al. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days monotherapy [abstract TUAB106]. 4th IAS Conference on AIDS Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia
75. Product Pipeline. Incyte Corp. Available from: http://www.incyte.com/ drugs-product-pipeline.html [Last accessed 13 December 2011]
76. Klibanov OM, Williams SH, Iler CA. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs 2010;11:940-50
77. Pipeline, Discovery & Development. Tobira Therapeutics. Available from: http://www.tobiratherapeutics.com/discovery.php [Last accessed 13 December 2011]
78. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-71
79. Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007;361:212-28 (Pubitemid 46551222)
80. LaBranche C, Kitrinos K, Howell R, et al. Clonal analysis of in vitro-derived viruses with reduced susceptibility to aplaviroc (873140, APL) shows wide ranges in IC50 and sequence changes [abstract 9]. Targeting HIV Entry-1st International Workshop; 2-3 December 2005; Bethesda, MD
81. Lewis M. A genotypic analysis of HIV-1 sequences from emerging resistant virus after in vitro serial passage with the CCR5 antagonist maraviroc (UK-427,857) [abstract 91]. 3rd European HIV Drug Resistance Workshop; 4-7 April 2005; Athens, Greece
82. Westby M. Maraviroc (MVC, UK-427,857)-resistant HIV-1 variants, selected by serial passage, are sensitive to CCR5 antagonists (GW873140, Schering-C, Schering-D) and T-20 (enfuvirtide) [abstract 65]. XIV International Drug Resistance Workshop; 7-11 June 2005; Quebec City, Canada
83. Craig C, Heera J, Lewis M, et al. Mechanisms of virologic failure with maraviroc in treatment-naive HIV-1-infected patients through 96 weeks [abstract 536]. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, CA
84. Waters L, Scourfield A, Marcano M, et al. The evolution of co-receptor tropism in patients interrupting suppressive HAART [abstract 439a]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada
85. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566-75 (Pubitemid 46185274)
86. Asmuth DM, Goodrich J, Cooper DA, et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010;54:394-7
87. Cuzin L, Trabelsi S, Mouillot G, et al. ANRS 145 Marimuno Study: a Multi-centre Prospective Pilot Study Evaluating Intensification of Stable Antiviral Therapy with Maraviroc in HIV-1-infected Patients with Insufficient Immune Restoration Despite Persistently Controlled Viral Replication [abstract PS1/6]. 13th European AIDS Conference; 12-15 October 2011; Belgrade, Serbia
88. Dragic T, Trkola A, Thompson DA, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-44 (Pubitemid 30313771)
89. Tsamis F, Gavrilov S, Kajumo F, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003;77:5201-8 (Pubitemid 36460934)
90. Maeda K, Das D, Ogata-Aoki H, et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 2006;281:12688-98 (Pubitemid 43855359)
91. Maeda K, Das D, Yin P, et al. Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights to mechanism of allosteric inhibition. J Mol Biol 2008;381:956-74
92. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008;73:789-800 (Pubitemid 351397884)
93. Shahlaei M, Madadkar-Sobhani A, Mahnam K, et al. Homology modeling of human CCR5 and analysis of its binding properties through molecular docking and molecular dynamics simulation. Biochim Biophys Acta 2011;1808:802-17
94. Garcia-Perez J, Rueda P, Alcami J, et al. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). J Biol Chem 2011;286:33409-21
95. Hall SE, Mao A, Nicolaidou V, et al. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 2009;75:1325-36
96. Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010;330:1066-71